This Phase Ib study combined programmed death-ligand 1 inhibitor, atezolizumab, with other immunomodulatory agents in locally advanced and metastatic solid tumors. Arms B-D evaluated atezolizumab plus interferon-α, with/without vascular endothelial growth factor inhibitor, bevacizumab, in renal cell carcinoma (RCC) and other solid tumors. Arm B predominantly recruited patients with previously treated RCC or melanoma to receive atezolizumab plus interferon α-2b. Arm C investigated atezolizumab plus polyethylene glycol (PEG)-interferon α-2a in previously treated RCC. Arm D evaluated atezolizumab plus PEG-interferon α-2a and bevacizumab. Primary objectives were safety and tolerability; secondary objectives included clinical activity. Combination therapy was well tolerated, with safety profiles consistent with known risks of individual agents. The most frequent treatment-related toxicities were fatigue, chills, and pyrexia. The objective response rate (ORR) in arm B was 20.0% overall and 17.8% in patients with previously treated checkpoint inhibitor-naive RCC (n = 45). No responses were reported in arm C. The highest ORR in arm D was 46.7% in patients with treatment-naive RCC (n = 15). Data showed preliminary clinical activity and acceptable tolerability of atezolizumab plus interferon α-2b in patients with previously treated checkpoint inhibitor-naive RCC and of atezolizumab plus PEG-interferon α-2a and bevacizumab in patients with treatment-naive RCC.
Current oncology (Toronto, Ont.). 2021 Dec 20*** epublish ***
Christian U Blank, Deborah J Wong, Thai H Ho, Todd M Bauer, Carrie B Lee, Fabiola Bene-Tchaleu, Jing Zhu, Xiaosong Zhang, Edward Cha, Mario Sznol
Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 Amsterdam, The Netherlands., David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA., Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA., Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN 37203, USA., Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Hoffmann-La Roche Ltd., Mississauga, ON L5N 5M8, Canada., Genentech, Inc., South San Francisco, CA 94080, USA., Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA.